본문으로 건너뛰기
← 뒤로

Case Report: Identification of a novel fusion co-existing with fusion in papillary thyroid carcinoma.

증례보고 1/5 보강
Frontiers in oncology 📖 저널 OA 100% 2021: 15/15 OA 2022: 98/98 OA 2023: 60/60 OA 2024: 189/189 OA 2025: 1004/1004 OA 2026: 620/620 OA 2021~2026 2023 Vol.13() p. 1123812
Retraction 확인
출처

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
환자: papillary thyroid carcinoma
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
In conclusion, we present the first case of a novel fusion co-existing with a known fusion in thyroid cancer.

Yu QX, Zhao WJ, Wang HY, Zhang L, Qin L, Zhang L

📝 환자 설명용 한 줄

fusions are validated oncogenic drivers of various adult and pediatric tumor types, including thyroid cancer, and serve as a therapeutic target.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Yu QX, Zhao WJ, et al. (2023). Case Report: Identification of a novel fusion co-existing with fusion in papillary thyroid carcinoma.. Frontiers in oncology, 13, 1123812. https://doi.org/10.3389/fonc.2023.1123812
MLA Yu QX, et al.. "Case Report: Identification of a novel fusion co-existing with fusion in papillary thyroid carcinoma.." Frontiers in oncology, vol. 13, 2023, pp. 1123812.
PMID 37188179 ↗

Abstract

fusions are validated oncogenic drivers of various adult and pediatric tumor types, including thyroid cancer, and serve as a therapeutic target. Recently, tropomyosin receptor kinase (TRK) inhibitors, such as entrectinib and larotrectinib, display promising therapeutic efficacy in -positive solid tumors. Although some fusion partners have been identified in thyroid cancer, the spectrum of fusion is not fully characterized. In this study, a dual fusion was identified by targeted RNA-Seq in a 47-year-old female patient with papillary thyroid carcinoma. The patient harbors a novel in-frame fusion between exon 13 and exon 2, co-existing with a known in-frame fusion between exon 4 and exon 14. The dual fusion was validated by Sanger sequencing and fluorescence hybridization (FISH) but lack TRK protein expression as defined by pan-TRK immunohistochemistry (IHC). We supposed the pan-TRK IHC result to be falsely negative. In conclusion, we present the first case of a novel fusion co-existing with a known fusion in thyroid cancer. These findings extend the spectrum of translocation partners in fusion, and the effect of dual fusion on TRK inhibitor therapy and prognosis needs long-term follow-up.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반

🟢 PMC 전문 열기